TP53 and colorectal carcinoma: As shown in Figs. 1A and S1C, combination treatment of Ganetespib plus RG-7388 yielded additive to synergistic reduction of cell viability in p53-proficient CRC cell lines HCT116 and RKO, compared to single treatments.